Spyre Therapeutics 在股票发行中筹集了 2.75 亿美元，以推进其炎症性肠病治疗。 Spyre Therapeutics raised $275 million in a stock offering to advance its inflammatory bowel disease treatments.

Spyre Therapeutics 以每股 18.50 美元的价格公开发行 1486 万股股票，筹集了约 2.75 亿美元的费用，承销商可以选择再购买多达 223 万股。 Spyre Therapeutics priced a public offering of 14.86 million shares at $18.50 each, raising about $275 million before fees, with an option for underwriters to buy up to 2.23 million more shares. 该交易预计将于2025年10月15日左右结束,由杰弗里斯,TD证券,Leerink合作伙伴,Stifel和Wedbush证券承销. The offering, expected to close around October 15, 2025, is underwritten by Jefferies, TD Securities, Leerink Partners, Stifel, and Wedbush Securities. 该公司侧重于炎症肠道疾病治疗,正在推进针对免疫途径的调查抗体。 The company, focused on inflammatory bowel disease treatments, is advancing investigational antibodies targeting immune pathways. 2025年3月7日的S-3号证交会登记表格涵盖了这项供货。 The offering is covered by a March 7, 2025, SEC-registered Form S-3. 前瞻性说明包括与市场状况和监管因素有关的风险。 Forward-looking statements include risks related to market conditions and regulatory factors.